{
    "code": "52028013",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52028013",
    "time": "2022-02-18 04:01:37",
    "許可證字號": "衛部藥輸字第028013號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "115\/01\/18",
    "發證\/登錄日期": "110\/01\/18",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202801308",
    "中文品名": "派力杉注射劑",
    "英文品名": "Paclitaxel Mylan",
    "適應症": "晚期卵巢癌、腋下淋巴轉移之乳癌，作為接續含杜薩魯比辛(DOXORUBICIN)在內之輔助化學療法、已使用合併療法(除非有禁忌，至少應包括使用ANTHRACYCLINE抗癌藥)失敗的轉移乳癌、非小細胞肺癌、愛滋病相關卡波西氏肉瘤之第二線療法；與CISPLATIN併用，作為晚期卵巢癌之第一線療法。與GEMCITABINE併用，可使用於曾經使用過ANTHRACYCLINE之局部復發且無法手術切除或轉移性之乳癌病患、與HERCEPTIN併用時，用於治療未接受過化學治療之轉移性且乳癌過度表現HER-2之病人。",
    "劑型": "270注射劑",
    "包裝": "5毫升、16.7毫升、30毫升玻璃小瓶裝 每盒100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "監視期滿學名藥",
    "監視期限": "",
    "主成分略述": "PACLITAXEL",
    "限制項目": "02輸　入 24監視期滿學名藥",
    "申請商名稱": "6201118216  台灣邁蘭有限公司",
    "申請商地址": "臺北市信義區信義路５段7號27樓",
    "主製造廠": [
        {
            "": "INDIA",
            "製程": ""
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000100",
            "成分名稱": "PACLITAXEL",
            "含量描述": "",
            "含量": "6.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "1.6.1 PI_20210323_clean-110-04-06.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028013&Seq=001&Type=9"
        },
        {
            "title": "Paclitaxel Injection - Label- Taiwan-110-04-06.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028013&Seq=002&Type=8"
        },
        {
            "title": "Paclitaxel Injection - Carton - Taiwan-110-04-06.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028013&Seq=001&Type=8"
        }
    ]
}